SCHEMBL5652209

SCHEMBL5652209

Nc1ccc(N2CCNC(=O)C2)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.49
GFER P55789 2/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
JAK2 O60674 1/20 0.36
BRD4 O60885 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCE Q02156 1/20 0.36
SCN9A Q15858 1/20 0.35
GAK O14976 1/20 0.35
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLC6A9 P48067 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5246344 0.87 ALDH1A1 (0.51) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL29931790 0.82 PKM (0.48) JAK2BRD4SCN9ASMN1; SMN2KMT2A
SCHEMBL23536039 0.82 PKM (0.48) JAK2BRD4SCN9ASMN1; SMN2KMT2A
SCHEMBL13419292 0.82 LMNA (0.39) ALDH1A1MAPTLMNAMAPK1JAK2
SCHEMBL31662793 0.82 ALDH1A1 (0.36) ALDH1A1JAK2BRD4PRKCHPRKCE
SCHEMBL2560082 0.80 ALDH1A1 (0.60) ALDH1A1MAPTJAK2BRD4PRKCH
SCHEMBL5373038 0.78 MEN1 (0.49) ALDH1A1MAPTLMNAMAPK1SCN9A
SCHEMBL16701552 0.78 ALDH1A1 (0.46) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL5653509 0.78 ALDH1A1 (0.61) ALDH1A1MAPTLMNASLC6A9POLB
SCHEMBL30738811 0.78 ALDH1A1 (0.61) ALDH1A1MAPTLMNASLC6A9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671058-B2 N-(3,4-disubstituted phenyl) salicylamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-03-02 US disclosed
US-7671058-B2 N-(3,4-disubstituted phenyl) salicylamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-03-02 US disclosed
US-20080227784-A1 N-(3,4-disubstituted phenyl) salicylamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-09-18 US disclosed
US-20080227784-A1 N-(3,4-disubstituted phenyl) salicylamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-09-18 US disclosed
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases CAPRARO HANS-GEORG 2007-09-13 US disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases ABL1, PRKCA, PRKCQ ALDH1A1 2948/4885MAPT 1440/4885GFER 4781/4885
US-20080227784-A1 N-(3,4-disubstituted phenyl) salicylamide derivatives STAT6, RELA, NFKB2 ALDH1A1 2263/4885MAPT 4713/4885GFER 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.